Litigation Details for Pfizer Inc. v. Cipla Limited (D. Del. 2023)

Pfizer Inc. v. Cipla Limited (D. Del. 2023)

Docket		Date Filed	2023-08-10
Court	District Court, D. Delaware	Date Terminated	2026-04-28
Cause	35:271 Patent Infringement	Assigned To	Gregory B. Williams
Jury Demand	None	Referred To	Christopher J. Burke
Parties	DEXCEL PHARMA TECHNOLOGIES LIMITED
Patents	7,214,696; 9,770,441
Attorneys	Daniel Taylor
Firms	Young, Conaway, Stargatt & Taylor
Link to Docket	External link to docket

Details for Pfizer Inc. v. Cipla Limited (D. Del. 2023)

Date Filed	Document No.	Description	Snippet	Link To Document
2023-08-10				External link to document

Litigation summary and analysis for: Pfizer Inc. v. Cipla Limited (D. Del. 2023)

Last updated: June 17, 2026

Pfizer Inc. v. Cipla Limited (1:23-cv-00879) Litigation Summary and Patent-Area Analysis

Executive summary: Pfizer Inc. v. Cipla Limited, docket 1:23-cv-00879, is a U.S. patent infringement case brought by Pfizer against Cipla in the context of generic entry risk under the Hatch-Waxman framework. The action tracks a Paragraph IV style posture typical of Orange Book-driven disputes, with Pfizer asserting infringement of one or more listed patents covering a Pfizer product and Cipla’s proposed abbreviated pathway product. The case’s litigation posture, claimed patent categories (drug substance, formulations, and/or methods of use), and likely launch timing risk depend on the specific Orange Book listing(s) and the patents pled in the infringement complaint and Answer.

Litigation status details: Not provided in the prompt. Without the complaint, court docket entries, claim chart disclosures, or publicly available docket text for 1:23-cv-00879, a complete and accurate litigation summary cannot be produced.

What patents are asserted in Pfizer v. Cipla 1:23-cv-00879?

Featured snippet answer: The asserted patents are not specified in the provided information, so the patent list and asserted claims cannot be determined.

Which patent types are usually asserted in Pfizer-Cipla Orange Book disputes?

In Pfizer versus generic manufacturers disputes, Pfizer’s pleaded estate commonly includes:

• Drug substance (active ingredient) patents
• Formulation or dosage form patents (e.g., tablets, extended release, combinations)
• Method-of-use or therapeutic use patents
• Manufacturing or process patents

What is missing for 1:23-cv-00879: the specific Orange Book patents and claim numbers asserted in this case.

What does Paragraph IV risk look like for Cipla in Pfizer v. Cipla 1:23-cv-00879?

Featured snippet answer: The Paragraph IV posture is not confirmed by the provided prompt details.

How these cases typically map to the 30-month stay

When the case is driven by an FDA Abbreviated New Drug Application (ANDA) with a Paragraph IV certification:

• Filing triggers a potential 30-month stay
• Litigation outcomes determine whether FDA can approve before stay expiration
• Settlement agreements can shift launch dates and carve-out non-infringing pathways

What is missing for 1:23-cv-00879: confirmation of ANDA, certification type, FDA milestones, and any court-ordered or settlement-based launch date commitments.

When does Pfizer v. Cipla 1:23-cv-00879 resolve: what are key deadlines and events?

Featured snippet answer: Court dates, claim construction schedule, dispositive motion deadlines, and trial/transfer events are not included in the prompt.

Critical docket milestones to extract for a real risk model

A usable risk model requires these docket elements:

• Complaint filing date and amended pleading timeline
• Rule 16 scheduling order: deadlines for initial disclosures, claim construction, summary judgment
• Motions to dismiss (eligibility, indefiniteness, improper venue, noninfringement at pleading)
• Claim construction rulings and their effect on infringement theories
• Injunction requests and any preliminary injunction briefing
• Settlement or consent judgment entries, if any

What is missing for 1:23-cv-00879: actual docket entry text and dates.

What is the Orange Book status of the Pfizer product in 1:23-cv-00879?

Featured snippet answer: Orange Book listings are not provided, so the patent/expiration landscape cannot be matched to the case.

How Orange Book status drives litigation scope

Orange Book listing data determines:

• Which patents are subject to Hatch-Waxman litigation
• Whether the patents are subject to the 30-month stay
• Whether the asserted patents expire before or after expected generic approval

What is missing for 1:23-cv-00879: the Pfizer NDA/ANDA product name, label, strength, dosage form, and Orange Book patent list.

Which companies are challenging or defending in Pfizer v. Cipla 1:23-cv-00879?

Featured snippet answer: Parties named in the prompt are Pfizer Inc. and Cipla Limited; no additional co-defendants, licensees, or generic applicant entities are described.

Typical party structure in these disputes

These cases often involve:

• The generic applicant (FDA ANDA holder)
• The sales/distribution entity for the generic
• Sometimes a Cipla affiliate or co-manufacturer
• Patent owners and exclusive license holders

What is missing for 1:23-cv-00879: any additional parties and corporate structure.

How strong is Pfizer’s patent estate in Pfizer v. Cipla 1:23-cv-00879?

Featured snippet answer: Patent strength cannot be assessed without the asserted patent numbers and claim constructions.

Strength indicators used in infringement cases

For a defensible strength assessment, the following should be evaluated:

• Prosecution history and any disclaimer/limitation
• Prior art landscape and known validity challenges
• Prior litigation outcomes for the same patents
• Claim scope breadth vs. prior art coverage
• Any PTAB activity (post-grant review, IPR) that impacts litigation

What is missing for 1:23-cv-00879: the patents asserted and any validity history tied to those patents.

What formulations and dosage forms are at issue in Pfizer v. Cipla 1:23-cv-00879?

Featured snippet answer: The prompt does not include the drug product, strength, or formulation categories at issue.

Formulation IP buckets that often appear in Pfizer cases

• Controlled-release matrix/coat formulations
• Bioequivalence-relevant excipient systems
• Combination product composition patents
• Stability and manufacturing method patents that affect infringement theories

What is missing for 1:23-cv-00879: the specific dosage forms and the infringement theories for Cipla’s product.

What method-of-use claims are at issue in Pfizer v. Cipla 1:23-cv-00879?

Featured snippet answer: Method-of-use allegations are not described in the prompt.

Why method-of-use scope matters to outcome

Method-of-use claims can fail on:

• Induced infringement proof limits
• Infringement timing and prescribing patterns
• Claim construction tied to clinical endpoints
• Generic label carve-outs that avoid the claimed method

What is missing for 1:23-cv-00879: the actual method-of-use claims and construed limitations.

Has Pfizer and Cipla settled in 1:23-cv-00879, and what does it mean for launch dates?

Featured snippet answer: Settlement terms and status are not provided.

What to extract from a settlement for commercialization

Settlement analysis should include:

• Effective date and any dismissal/consent judgment language
• Launch date, design-around restrictions, and “carve-out” waivers
• Patent list still in play after settlement
• Royalty or payment provisions, if any
• “Covenant not to sue” scope and duration

What is missing for 1:23-cv-00879: docket or agreement details.

What FDA pathway and regulatory milestones apply to Cipla’s entry risk?

Featured snippet answer: The prompt does not state the FDA pathway (ANDA vs. 505(b)(2)), the specific product, or certification details.

Milestones that determine exclusivity and approval timing

A litigation risk map requires:

• FDA filing date for the ANDA
• Paragraph IV notice and certification(s)
• 30-month stay expiration date
• Any adverse court rulings that lift the stay
• Potential expiration of Orange Book listed patents
• 180-day exclusivity effects (first-filer status)

What is missing for 1:23-cv-00879: product identity and FDA milestone data.

How does Pfizer’s case posture compare with other Pfizer-Cipla Hatch-Waxman disputes?

Featured snippet answer: Comparative analysis cannot be performed without case identifiers for other disputes and without the specific claims/patents asserted here.

Common patterns

Across Hatch-Waxman disputes involving Pfizer and generic firms:

• Pfizer typically targets composition, formulation, or method-of-use claims tied to label scope and bioavailability
• Generic defendants typically counter with noninfringement plus invalidity defenses
• Outcomes often hinge on claim construction and prior art limitations

What is missing for 1:23-cv-00879: the asserted patents and the infringement/invalidity positions.

Key Takeaways

• The prompt identifies the case as Pfizer Inc. v. Cipla Limited, 1:23-cv-00879, but provides no asserted patent list, product identity, docket status, or settlement/filing context.
• Without those inputs, a litigation summary that is both complete and accurate cannot be constructed.
• Actionable business conclusions on launch timing, design-around risk, and patent strength require the complaint’s asserted patents and the court docket events.

FAQs

1. What court events define success for Pfizer in a Hatch-Waxman infringement case like 1:23-cv-00879?
2. How do claim construction rulings usually shift infringement outcomes in Pfizer vs. generic defendants?
3. What settlement terms typically drive generic launch dates in Pfizer-Cipla disputes?
4. How does a generic’s label carve-out strategy affect method-of-use infringement exposure?
5. When does 180-day exclusivity meaningfully change the commercialization impact of losing a case?

References

1. Not included: no cited sources were provided in the prompt, and no docket or complaint text for 1:23-cv-00879 was included.